AI Science Tracker

RFdiffusion

12 discoveries name this family, 2023 to 2026

Where RFdiffusion appears in the catalog

Why linked?

These associations match family names in discovery titles and technology text. They are not verified model-version assignments or causal attribution. Missing links do not establish absence of use. A record may link to multiple families.

Represented fields

biology · 10 linked records
medicine · 2 linked records

Test contexts

direct test · 12 linked records

Annotation coverage

Evidence annotation present · 12 linked records

Examples

Up to three linked records, newest publication date first, then stable ID. This selection is not a ranking.

Discoveries

Deep-learning design of zinc metalloproteases

RFdiffusion2 for Molecular Interfaces designs zinc-dependent proteases for peptide-bond hydrolysis. The primary paper reports cleavage at the targeted bond in 36% of 135 designs and selected designs that cleave disease-associated proteins in vitro. These biochemical results do not establish therapeutic efficacy.

Technology: RFdiffusion2 for Molecular Interfaces (RFD2-MI); AlphaFold 3

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The source reports the study-specific result summarized here.
  • Still unknown: Independent replication and broader deployment or clinical benefit are not established by this source review.
  • AI role: RFD2-MI generates scaffolds around zinc catalytic and peptide-binding geometries; computational filtering guided experimental testing.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12667880/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 16 Nov 2026. Review scope: Primary-source abstract and publication metadata reviewed; full text scope is specified in source_checks..

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

AI-designed bacterial anti-defense proteins enable phage infection and plasmid retention

RFdiffusion-based de novo binder design and experimental screening produced synthetic proteins that inhibited three bacterial defense systems: Thoeris and Avs1 in Bacillus subtilis assays, and DdmDE in Vibrio cholerae. Five designed proteins inhibited Thoeris and nine inhibited Avs1 in the reported screens. An engineered SBSphiJ phage carrying both anti-Thoeris and anti-Avs1 proteins replicated in B. subtilis cells expressing both defenses. In native V. cholerae O1 El Tor, two of four tested DdmDE binders improved plasmid resistance to clearance.

Technology: RFdiffusion de novo binder design, ProteinMPNN sequence design and AlphaFold2/3 structure-guided candidate scoring

Family AlphaFold: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: RFdiffusion-based de novo binder design and experimental screening produced synthetic proteins that inhibited three bacterial defense systems: Thoeris and Avs1 in Bacillus subtilis assays, and DdmDE in Vibrio cholerae.
  • Still unknown: These are laboratory proof-of-concept results in three bacterial defense systems and specific strains; they do not demonstrate therapeutic phage efficacy in animals or humans. Binder success was low relative to the computationally designed candidate sets, and the authors note that a verified binder may not work against homologous defense proteins. The native V. cholerae result was tested for plasmid retention, not general transformation across clinical isolates. The earlier bioRxiv version is the same study and is not a separate record.
  • AI role: RFdiffusion generated candidate binder backbones for selected target sites in the Thoeris, Avs1 and DdmDE defense proteins; ProteinMPNN designed sequences and AlphaFold-based co-folding/scoring prioritized candidates for experiments. The selected synthetic binders were tested for defense inhibition, direct interactions and ability to restore phage infection or plasmid retention. The measured anti-defense functions and engineered-phage outcomes are the paper-specific results enabled by AI-guided protein design.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13402655/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

CycleRFdiffusion-designed TP4 is a reproducible cyclic peptide binder to TREM2

A structure-conditioned workflow combining CycleRFdiffusion, ProteinMPNN and HighFold generated and screened 1,500 cyclic peptide–TREM2 complexes and prioritized four candidates. The lead TP4 showed weak but reproducible TREM2 binding in spectral-shift, microscale-thermophoresis and surface-plasmon-resonance assays. The authors report favorable plasma stability and moderate metabolic stability, presenting the work as an initial proof of concept for TREM2-targeted cyclic binders.

Technology: CycleRFdiffusion backbone design, ProteinMPNN sequence design and HighFold structural prediction/screening

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The lead TP4 showed weak but reproducible TREM2 binding in spectral-shift, microscale-thermophoresis and surface-plasmon-resonance assays.
  • Still unknown: The only reported lead, TP4, is described as a weak binder. The evidence is biophysical binding and stability profiling, not demonstrated modulation of TREM2 signaling, microglial function, disease pathology or therapeutic efficacy. Treat this as proof-of-concept binder discovery.
  • AI role: The AI pipeline generated and ranked 1,500 candidate cyclic peptide–TREM2 complexes based on structure, sequence and predicted energetics, from which four were selected for experiments; TP4 was then assessed with multiple orthogonal binding assays.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41435973/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

RFdiffusion2 scaffolds enzyme active sites at atomic level

RFdiffusion2 scaffolded all 41 active sites in a diverse benchmark, compared with 16 for previous methods. Designs were tested experimentally, with fewer than 96 sequences needed per case to find active enzymes across three catalytic mechanisms. The journal abstract's three-mechanism count conflicts with a five-reaction claim in the Institute for Protein Design announcement, so the abstract should be treated as authoritative.

Technology: RFdiffusion2

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Designed enzymes were expressed and screened experimentally for retroaldolase, cysteine hydrolase and zinc hydrolase activity, with kinetic constants measured for the best variants.
  • Still unknown: Authors state the designs are not as active as native enzymes, the theozymes may miss interactions needed for high activity, and scaffolding catalytic atoms does not guarantee proficient enzymes.
  • AI role: RFdiffusion2 generated scaffolds from atom-level active-site descriptions, LigandMPNN assigned sequences, and structure predictors filtered designs before testing.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12791007/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Computational design of zinc metallohydrolases with RFdiffusion2

RFdiffusion2 designed zinc metallohydrolases from quantum-chemistry-derived active-site geometries. The first round of 96 designs produced an enzyme with catalytic efficiency of 16,000 M-1 s-1, and a second round of 96 yielded three more highly active enzymes, with k/K up to 53,000 M-1 s-1. Crystal structures (PDB 9PYJ, 9PYL) were determined, but the evidence covers one designed enzyme family.

Technology: RFdiffusion2 with quantum-chemistry active-site models

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: From 96 designs, the best had kcat/KM of 16,000 M^-1 s^-1; a second round of 96 gave three more active enzymes, up to 53,000 M^-1 s^-1 and kcat up to 1.5 s^-1. The crystal structure of the most active design is very close to the model.
  • Still unknown: Use in practical applications is not reported in the abstract.
  • AI role: RFdiffusion2 designed zinc metallohydrolases from quantum-chemistry active sites; PLACER and Chai-1 analysed the designs.

Evidence sources: https://doi.org/10.1038/s41586-025-09746-w

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: other. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Riff-Diff: computational enzyme design by catalytic motif scaffolding

The December 2025 Nature version reports Riff-Diff designs for retro-aldol and Morita-Baylis-Hillman reactions, with activities comparable to enzymes optimized by experimental evolution. Six high-resolution structures support near-atomic active-site placement. The abstract describes a hybrid of machine learning and atomistic modelling. The work also has a bioRxiv preprint first indexed in August 2024; the January 2026 journal issue is later than online publication.

Technology: Riff-Diff (RFdiffusion with rotamer-based motif placement)

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Designed-enzyme activity and six experimental high-resolution structures.
  • Still unknown: Not assessed: full-paper success rates, thermal assays and supplementary data.
  • AI role: Riff-Diff combines learned protein generation and atomistic catalytic-motif scaffolding.

Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.1038%2Fs41586-025-09747-9%22&resultType=core&format=json · https://www.tugraz.at/en/news/article/enzyme-design-ai-riff-diff

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Serine hydrolases designed from scratch

The April 2025 Science version describes RFdiffusion enzyme backbones and PLACER assessment of catalytic-state ensembles. Laboratory characterization found catalytic efficiency up to 2.2 × 10^5 M^-1 s^-1, crystal structures with C-alpha RMSD below 1 angstrom, and catalysts in five folds different from natural serine hydrolases. This summary follows the abstract and figure descriptions; an earlier bioRxiv version was posted in August 2024.

Technology: RFdiffusion and PLACER

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Enzyme activity assays and crystallographic comparison of designed catalysts.
  • Still unknown: Not assessed: complete design success rates and supplementary data.
  • AI role: RFdiffusion generated backbones; PLACER assessed catalytic-state geometry.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39946508/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 275 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Computer-designed proteins neutralize snake toxins

Small, stable proteins designed with AI bind and neutralize three-finger toxins from cobras and mambas in the lab; in mice, they yield 80–100% survival against lethal neurotoxin doses, depending on the toxin. Laboratory and animal studies only; traditional antivenoms remain central.

Technology: AI protein design (RFdiffusion)

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Lab tests showed the designed proteins neutralized multiple subtypes of three-finger toxins; in mice they gave complete protection from lethal neurotoxin exposure, with 80-100% survival depending on the toxin and antitoxin.
  • Still unknown: The page does not mention human trials, toxin types other than elapid three-finger toxins, and traditional antivenoms remain central to treatment.
  • AI role: Designed small, stable proteins on the computer that bind key regions of the toxins.

Evidence sources: https://www.ipd.uw.edu/2025/01/neutralizing-deadly-snake-toxins/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 196 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

GRACE designs two carbonic-anhydrase-like enzymes with measured catalytic activity

The GRACE workflow combined RFdiffusion structure generation, ProteinMPNN sequence design, CLEAN enzyme classification and solubility/structure filtering to select two carbonic-anhydrase-like sequences from 10,000 candidates. The authors report experimental expression and carbonic anhydrase activity: dCA12_2 at 400 WAU/mL and dCA23_1 at 260 WAU/mL in the reported assay.

Technology: GRACE (RFdiffusion, ProteinMPNN and CLEAN, with computational solubility/structural filters)

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The authors report experimental expression and carbonic anhydrase activity: dCA12_2 at 400 WAU/mL and dCA23_1 at 260 WAU/mL in the reported assay.
  • Still unknown: The reported activity values are from the study's carbonic-anhydrase assay and do not establish purified-enzyme kinetics, physiological CO2-fixation performance, or industrial utility. The designs and validation are a two-protein proof of concept; no independent replication assessed.
  • AI role: The generative-design workflow produced structures/sequences and machine-learning function classification prioritized two candidates from a 10,000-sequence pool; researchers expressed both and measured carbonic-anhydrase activity.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11669173/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 89 of works of the same type, year and subfield (OpenAlex work metrics, 20 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Antibodies designed from scratch with RFdiffusion

Baker’s group showed RFdiffusion can be adapted to generate antibodies: in laboratory tests, designs bound influenza virus and other targets as intended. Proof-of-concept study, first circulated as a preprint in March 2024; experts quoted by Nature call it promising but an early step; no affinity values reported.

Technology: RFdiffusion

Family RFdiffusion: profile · models page

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: direct test
  • Tested: Laboratory tests confirmed that the designed antibodies bind influenza virus and other targets as intended; no affinity values are reported.
  • Still unknown: The work is described as a proof-of-concept study, and no specific limitations are listed.
  • AI role: RFdiffusion was tuned to generate antibodies from scratch.

Evidence sources: https://www.ipd.uw.edu/2024/04/nature-a-landmark-moment-scientists-use-ai-to-design-antibodies-from-scratch/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Designed proteins bind peptides with the highest affinity reported

Using RFdiffusion and ProteinMPNN, researchers designed proteins that bind helical peptides such as glucagon, neuropeptide Y and parathyroid hormone, with what the authors consider the highest reported affinity for a computer-generated biomolecule. They detect low concentrations of peptides in human serum and withstand heat; a parathyroid-hormone biosensor produced a 21-fold increase in bioluminescence. The press release gives no affinity values.

Technology: RFdiffusion and ProteinMPNN

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Designed binders were tested in the lab for peptide detection (mass spectrometry, including low-concentration peptide detection) and a bioluminescence biosensor produced a 21-fold signal increase with parathyroid hormone; the press release gives no affinity values.
  • Still unknown: The abstract does not describe how affinity was measured, does not mention serum testing, and states no limitations; the press release states no limitations.
  • AI role: RFdiffusion, extended for flexible targets and partial diffusion, designed binders to helical peptides, de novo or by refining other designs.

Evidence sources: https://www.ipd.uw.edu/2023/12/ai-generates-proteins-with-exceptional-binding-strengths/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06953-1&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 290 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

RFdiffusion: designing new proteins with a diffusion model

A guided diffusion model generates tailored protein structures, such as proteins that bind tightly to another molecule, and outperforms previous methods across a wide range of problems. The post says only that ‘a useful fraction’ of generated designs work as intended, without figures; the software was released in March 2023.

Technology: RFdiffusion

Family RFdiffusion: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Designs were characterized experimentally (symmetric assemblies, metal-binding proteins, protein binders), and a cryo-EM structure of a designed binder was nearly identical to the design model; the abstract reports no overall success rates.
  • Still unknown: The abstract states no explicit limitations; the press post gives no success rates, sample sizes or benchmark numbers and says only that a useful fraction of designs work.
  • AI role: A generative diffusion model fine-tuned from RoseTTAFold generated protein backbones for monomer, binder, oligomer, enzyme scaffold and motif designs.

Evidence sources: https://www.ipd.uw.edu/2023/07/ai-tools-are-designing-entirely-new-proteins-that-could-transform-medicine/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06415-8&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 2729 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.